Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo. (DepIST-H)
Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo
研究概览
详细说明
Title: Prevalence and longitudinal follow-up over 2 years of anal lesions, HPV infection and associated sexually transmitted infections among men who have sex with men (MSM) in Lomé, Togo (ANRS12400 DepIST-H)
Main objective: To estimate the prevalence and incidence of anal lesions (condyloma, dysplasia and anal cancers) according to HIV status among MSM in Lomé, Togo
Specific objectives :
To estimate the prevalence of HPV infection at baseline (M0) at anal and oropharyngeal sites To describe the persistence of HPV infection at Year 1 and 2 at the anal and oropharyngeal sites To describe the recurrence of anal lesions at Year 1 and 2 To estimate prevalence and incidence of associated STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex Virus type 2, Mycoplasma genitalium, Trichomonas vaginalis) HBV, HCV and syphilis
Methods :
This study is a prospective cohort with a 2-year follow-up of 200 MSM in Lomé (100 HIV- and 100 HIV+). Three data collection systems are integrated into the cohort: (i) clinical data, (ii) socio-behavioural questionnaires, and (iii) biological data.
Sample size: 200 participants (100 HIV+ and 100 HIV-)
Interventions :
Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).
Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.
Statistical analysis methods :
Use of mixed approaches. For quantitative indicators, descriptive analysis techniques, bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or Fisher test for categorical variables) and multivariate analysis (logistic regression).
To estimate the incidence if the STIs, Kaplan-Meier curves, Cox models analyses will be conducted.
As the cohort is open and non-randomized, preliminary analyses will be conducted during the collection.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Didier Koumavi Ekouevi
- 电话号码:+228 99 68 67 35
- 邮箱:didier.ekouevi@gmail.com
研究联系人备份
- 姓名:Arnold Sadio
- 邮箱:sadioarnold@gmail.com
学习地点
-
-
-
Lomé、多哥
- 招聘中
- ONG, Espoir Vie Togo
-
接触:
- Ephrem Mensah, MD
- 电话号码:+228 90 01 64 11
- 邮箱:ephremensah@hotmail.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Being a male aged 18 or over
- Self-reporting as being a MSM
- Wishing to be part of a regular clinical follow-up
- Agreeing to participate in the study and signing the informed consent form
- Live in Lomé
- Having had anal intercourse within the past six months prior to inclusion visit
- Regardless of HIV status (infected or not)
- Whether or not the participant has already taken antiretrovirals
Exclusion Criteria:
- Participation in another biomedical and/or behavioural study on HIV, viral hepatitis or sexually transmitted infections (CohMSM ANRS 12324-EF cohort of Lomé)
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Prevalence at inclusion of anal lesions
大体时间:at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Prevalence of anal lesions at baseline
大体时间:at Day 0
|
According to HIV status among MSM in Lomé, Togo
|
at Day 0
|
Incidence of anal lesions
大体时间:at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the number of worsening events of anal cytological lesions
大体时间:at 12 month and 24 month
|
According to HIV status among MSM in Lomé, Togo
|
at 12 month and 24 month
|
Describe the proportion of recurrence of anal lesions
大体时间:at 12 month and 24 month
|
According to HIV status among MSM who received available treatment, in Lomé, Togo
|
at 12 month and 24 month
|
Prevalence of HPV infections
大体时间:at Day 0
|
at Day 0
|
|
Incidence of HPV infection
大体时间:at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of persistent HPV infections
大体时间:at 12 month and 24 month
|
at 12 month and 24 month
|
|
Describe the proportion of clearance of HPV infections
大体时间:at 12 month and 24 month
|
in the same individual, on anal and oral specimens, based on HIV status.
|
at 12 month and 24 month
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
大体时间:At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C
大体时间:At Day 0, at 12 month and 24 month
|
According to HIV status
|
At Day 0, at 12 month and 24 month
|
Determination of different Chlamydia trachomatis strains
大体时间:At Day 0
|
At Day 0
|
|
Determination of antibiotic resistance profiles for Neisseria gonorrhoeae, Mycoplasma genitalium and Chlamydia trachomatis
大体时间:At Day 0
|
According to HIV status
|
At Day 0
|
Incidence of HIV
大体时间:at 12 month and 24 month
|
at 12 month and 24 month
|
合作者和调查者
合作者
调查人员
- 首席研究员:Charlotte Charpentier、Hôpital Bichat Claude Bernard, Paris, France
- 首席研究员:Didier Ekouevi、Lomé University, Togo
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
艾滋病毒感染的临床试验
-
Hospital Clinic of Barcelona完全的
-
Rajavithi Hospital未知研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的免疫状态 | 研究在放疗前和放疗最后一周接受放疗的 HIV 癌症患者的 HIV 病毒载量泰国
-
National Institute of Allergy and Infectious Diseases...完全的HIV-1 感染 | HIV抗体 | 中和抗体 | 病毒载量 | 单克隆抗体美国
-
AIDS Healthcare FoundationUniversity of California, Los Angeles完全的
-
ANRS, Emerging Infectious DiseasesInstitut National de la Santé Et de la Recherche Médicale, France; University of Bergen; Centre... 和其他合作者完全的
-
Hospital Universitari Vall d'Hebron Research InstituteGilead Sciences完全的
-
Hospital Universitari Vall d'Hebron Research InstituteUniversity Hospital, Ghent; IrsiCaixa完全的
STIs screening and care的临床试验
-
Zealand University HospitalUniversity of Copenhagen; Steno Diabetes Center Copenhagen; Holbaek Sygehus招聘中